The Only Industry-Led Meeting Uniting Pharma and Biotech from the East Coast to Network and Discuss New Trends and Innovations in Tumor Models

In the wake of the FDA Modernization Act and translational rates of cancer drugs into the clinic at just 20%, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery.

The 12th Annual Tumor Models Boston Summit is the only industry-led meeting uniting 200+ industry experts from pharma, biotech, academic KOLs and preclinical CROs to delve into the latest case studies in leveraging PDX models, genetically engineered mouse models, advanced 3D in vitro models and more. Join industry leaders developing teams in preclinical, translational, pharmacology, discovery, pharmacodynamics, toxicity and biology to optimize and implement more translatable oncology models.

Your World Class 2024 Speaker Faculty Includes:

A Snapshot of What 2024 Has In-Store:

1

Discover how to utilize PDX models to optimize patient representation with AstraZeneca

2

Develop and understand the mode of action of tumor models using in vivo imaging biomarkers, with Merck

3

Identify potential biomarkers before evaluating in the clinic, presented by Abbvie

4

Use in vivo and in vitro models to effectively recapitulate the tumor stroma and fibroblasts, with Amgen

5

Elucidate an in vivo gene therapy approach to reprogram the patients’ immune cells to fight cancer, with exclusive insights from Sanofi

6

Uncover the latest advances in utilizing humanized mouse models, GEMMs, CDX, PDX & organoids to optimize IO preclinical research & improve clinical translation

Companies That Shared Insights In 2023:

31881-Speakers (4)

Our 2024 Partners:

Lide Logo
MissionBio-Logo_FINAL_corporate_CMYK
gempharmatech_owler_20210623_072714_original
DRL
certis-logo-lockup-CMYK (002)
Champions_Oncology_logo
XenoStart_Final Logo Files_All
Wuxi
Charles River
ChemPartner-Logo-2023_Ombre-2048x328
td2-logo
StudyLog
reaction
tempus
Kiyatec_logo_new
epo

Other Events in the Series